Compare Vaxcyte Inc. Common Stock (PCVX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Vanguard Growth Index Fund ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Vanguard Growth Index Fund ETF trades at $89.32 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 36.6× Vaxcyte Inc. Common Stock's market cap, and Vanguard Growth Index Fund ETF is more actively traded (4,518,036 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| PCVX | VUG | |
|---|---|---|
Market Cap | $10.51B | $384.60B |
Volume | 2,644,694 | 4,518,036 |
Sector | Health | Sector/Thematic |
52-Week High | $73.82 | $92.64 |
52-Week Low | $40.32 | $70.00 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VUG trades at $91.75, up 0.12% with a bullish technical outlook supported by moving averages. The ETF maintains strong historical performance with 12% average annual returns since 2004, concentrated in mega-cap technology stocks like Nvidia, Apple, and Microsoft. Recent dividend activity shows a $0.09 distribution scheduled for September 2026.
Long-term growth prospects remain favorable given VUG's track record and low expense ratio, though concentration risk in technology holdings and recent underperformance versus value funds present headwinds. The ETF suits investors with multi-decade horizons seeking large-cap growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
